Insights - In one of the most shocking accounting errors we’ve seen in pharma, Salix Pharmaceuticals (SLXP) reported on Thursday after the bell that it has nine months of … Continue Reading
Read nowInsights - The FDA has removed a clinical hold prohibiting Geron Corp (GERN) from dosing new patients with its investigational cancer drug imetelstat, sending the company’s stock higher by 35% … Continue Reading
Read nowInsights - Synergy Pharmaceuticals (SGYP) cleared out a major overhang on Wednesday Oct. 28 – evidenced by the stock’s 15% move higher in the session – with the … Continue Reading
Read nowResearch - Pain Therapeutics (PTIE) and Durect (DRRX) just announced that Pfizer (PFE) will discontinue development of Remoxy (Extended-Release oxycodone) and will return all rights to Pain Therapeutics. Pain Therapeutics had the rights to … Continue Reading
Read nowInsights - Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).
Read nowInsights - FDA put the breaks on Repros (RPRX) on Friday when it indicated that an upcoming meeting would not be the pre-NDA meeting investors expected.
Read nowInsights - At a medical meeting this week Alnylam Pharmaceuticals (ALNY) reported six-month data from an ongoing study of patisiran (ALN-TTR02) in the rare disorder TTR-mediated amyloidosis (ATTR) in patients with … Continue Reading
Read now
